We also have one preclinical stage product candidate, CB-001 (a GPR120 agonist). Following is a review of PBC and NASH and our development progress in each indication. The primary outcome measure will be the composite biochemical responder rate at 52 weeks. In addition, over two dozen other compounds are currently in Phase 2 development in NASH. Finally, corresponding changes in GGT were -0.6%, -29.0%, -46.1% and -35.0%. 8226; Financial reporting and compliance. CB-0406 is a derivative of halofenate. We control only certain aspects of our CSPs' activities. As a result, increasingly high barriers are being erected to the entry of new products. Coverage policies and third-party reimbursement rates may change at any time. Charles A. McWherter, Ph.D. has served as our Chief Scientific Officer since 2013. We have incurred significant net losses since our inception. We do not maintain "key person" insurance for any of our executives or other employees. We may be the target of this type of litigation in the future.
